Watchlist Price Alert

Verve Therapeutics Inc. (VERV)

NASDAQ: VERV · Real-Time Price · USD

4.17

-0.18 (-4.14%)

At close: May 13, 2025, 3:59 PM

4.20

0.57%

After-hours: May 13, 2025, 07:42 PM EDT

-4.14% (1D)

Bid	4.05
Market Cap	372.17M
Revenue (ttm)	32.33M
Net Income (ttm)	-198.71M
EPS (ttm)	-2.35
PE Ratio (ttm)	-1.78
Forward PE	-1.57
Analyst	Strong Buy

Ask	4.25
Volume	2,270,508
Avg. Volume (20D)	2,884,083
Open	4.32
Previous Close	4.35
Day's Range	4.04 - 4.38
52-Week Range	2.87 - 9.30
Beta	1.83

About VERV

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol VERV

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for VERV stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Verve Therapeutics Inc. is scheduled to release its earnings on May 27, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 weeks ago

+20.63%

Verve Therapeutics shares are trading higher after... Unlock content with Pro Subscription

4 weeks ago

+26.38%

Verve Therapeutics shares are trading higher after the company announced a 69% LDL-C reduction with VERVE-102 in its Heart-2 trial.

News

2 weeks ago · fool.com

1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street

Equity markets have been volatile this year due to macroeconomic and geopolitical factors. Many of the world's largest corporations haven't escaped the sell-off, and it's hard to predict what's next.

3 weeks ago · fool.com

Why Verve Therapeutics Zoomed 40% Higher This Week

Good news from the laboratory and a clutch of bullish analyst notes were the drivers behind Verve Therapeautics' (VERV 2.00%) big stock price leap this week. By the time the dust cleared, the biotech ...

3 weeks ago · seekingalpha.com

Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'

VERV's VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Also, LLY may opt into VERVE-102's development later this year, which would help VERV by covering one-third of the...

4 weeks ago · zacks.com

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study

Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.

4 weeks ago · fool.com

Why Verve Therapeutics Is Skyrocketing Today

Verve Therapeutics (VERV 22.57%) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m.

1 month ago · benzinga.com

Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose

Verve Therapeutics Inc VERV on Monday released initial data from the Heart-2 Phase 1b trial of VERVE-102 in patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary ar...

2 months ago · zacks.com

Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates

Verve Therapeutics (VERV) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.69 per share a year ago.